KELER TIBOR bought CLDX
June 25, 2026 · Form 4 insider transaction
KELER TIBOR bought 115,000 shares of Celldex Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 4 days after the transaction.
Direction
Acquired (buy-side)
Shares
115,000
Price
$0.00
Total value
N/A
InsiderKELER TIBOR
RoleOfficer
SecurityIncentive Stock Option (right to buy)
Transaction codeA: Grant or award
Transaction dateJune 25, 2026
Filing dateJune 29, 2026
Shares owned after115,000
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.; 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.